ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in January

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 31,141,614 shares, a decline of 5.9% from the January 12th total of 33,104,937 shares. Currently, 24.5% of the company’s stock are sold short. Based on an average trading volume of 2,474,487 shares, the days-to-cover ratio is presently 12.6 days.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Principal Financial Group Inc. raised its stake in shares of ZIOPHARM Oncology by 7.5% during the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares during the period. Amalgamated Bank raised its stake in shares of ZIOPHARM Oncology by 12.9% during the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the period. Nationwide Fund Advisors raised its stake in shares of ZIOPHARM Oncology by 3.0% during the 2nd quarter. Nationwide Fund Advisors now owns 72,799 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 2,127 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of ZIOPHARM Oncology by 6.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 4,826 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of ZIOPHARM Oncology by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock worth $649,000 after purchasing an additional 7,946 shares during the period. Institutional investors own 40.27% of the company’s stock.

ZIOP has been the topic of a number of analyst reports. BidaskClub downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Zacks Investment Research reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a report on Saturday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $9.50 price objective on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. ValuEngine cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. ZIOPHARM Oncology has an average rating of “Hold” and a consensus price target of $12.67.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) opened at $3.89 on Friday. The company has a market capitalization of $552.24, a price-to-earnings ratio of -7.48 and a beta of 1.42. ZIOPHARM Oncology has a 52 week low of $3.33 and a 52 week high of $7.88.

COPYRIGHT VIOLATION WARNING: “ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 5.9% in January” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/10/ziopharm-oncology-inc-ziop-short-interest-down-5-9-in-january.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply